COVID-19 drug repurposing research explained

Drug repositioning (also known as drug repurposing, re-profiling, re-tasking, or therapeutic switching) is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed.[1] This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments.[2] [3] [4] Other research directions include the development of a COVID-19 vaccine[5] and convalescent plasma transfusion.[6]

Several existing antiviral medications, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV/AIDS, and malaria, have been researched as potential COVID-19 treatments, with some moving into clinical trials.[7] [8] [9]

In a statement to the journal Nature Biotechnology in February 2020, US National Institutes of Health Viral Ecology Unit chief Vincent Munster said, "The general genomic layout and the general replication kinetics and the biology of the MERS, SARS and [SARS-CoV-2] viruses are very similar, so testing drugs which target relatively generic parts of these coronaviruses is a logical step".

Background

Outbreaks of novel emerging infections such as COVID-19 pose unique challenges to discover treatments appropriate for clinical use, given the small amount of time available for drug discovery.[10] Since the process of developing and licensing a new drug for COVID-19 was expected to pose a particularly long delay, researchers have been probing the existing compendium of approved antivirals and other drugs as a cost-effective strategy in the meantime.[10] In early 2020 hundreds of hospitals and universities began their own trials of existing safe drugs with repurposing potential against COVID-19.[11]

Drug repurposing usually requires three steps before taking the drug across the development pipeline: recognition of the right drug; systematic evaluation of the drug effect in clinical models; and estimation of usefulness in phase II clinical trials.[12]

One approach used in repositioning is to look for drugs that act through virus-related targets such as the RNA genome (i.e. remdesivir). Another approach concerns drugs acting through polypeptide packing (i.e. lopinavir).[10]

The rush to publish papers about the pandemic resulted in some scandals of inaccurate scientific publications.[13] Some early studies reporting the efficacy of hydroxychloroquine and remdesivir convinced drug agencies such as Food and Drug Administration (FDA) and European Medicines Agency to approve the off-label use by issuing Emergency Use Authorizations which were later revoked as new evidence showed these drugs have no effect on the course of COVID-19.[14] These false-positive results can be explained in terms of the base-rate fallacy and the rapid changes in clinical guidance regarding COVID-19 treatment could have been avoided if mechanistic evidence for and against repurposing candidates were carefully assessed[15] and the standard evidence amalgamation tools such as meta-analysis were routinely applied.[16]

Monoclonal antibodies

Monoclonal antibodies under investigation for repurposing include anti-IL-6 agents (tocilizumab)[17] and anti-IL-8 (BMS-986253).[18] (This is in parallel to novel monoclonal antibody drugs developed specifically for COVID-19.)

Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).[19] [20] It has been studied to see if it can improve the prognosis for patients with COVID-19 pneumonia and systemic hyperinflammation. One small study indicated some beneficial effects of treatment with mavrilimumab compared with those who were not.[21]

In January 2021, the UK National Health Service issued guidance that the immune modulating drugs tocilizumab and sarilumab were beneficial when given promptly to people with COVID-19 admitted to intensive care, following research which found a reduction in the risk of death by 24%.[22]

Tocilizumab

Anticoagulants

Medications to prevent blood clotting have been suggested for treatment, and anticoagulant therapy with low-molecular-weight heparin appears to be associated with better outcomes in severe COVID‐19 showing signs of coagulopathy (elevated D-dimer).[23] Several anticoagulants have been tested in Italy, with low-molecular-weight heparin being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.[24] [25]

Scientists have identified an ability of heparin to bind to the spike protein of the SARS-CoV-2 virus, neutralising it, and proposed the drug as a possible antiviral.[26]

A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on 14 April.[27]

The anticoagulant dipyridamole is proposed as a treatment for COVID-19,[28] and a clinical trial is underway.[29]

Antidepressants

Many antidepressants have anti-inflammatory properties. An observational study in Paris area hospitals found that COVID-19 patients admitted to the hospital who were already taking an antidepressant had 44% less risk of intubation or death.[30] [31] The potential mechanisms how fluvoxamine and fluoxetin are contributing to prevent the development of severe respiratory symptoms of COVID-19 by protecting the type 2 lung alveolar cells have been summarized in a review in March 2022.[32]

Fluvoxamine

In October 2021, the TOGETHER trial, a large clinical trial in Brazil, reported that treating high-risk outpatients with an early diagnosis of COVID-19 with 100 mg fluvoxamine twice daily for 10 days reduced by up to about 65% the risk of hospitalization. The effect was reduced to about 32% with low adherence, possibly due to intolerance. There was also a reduction in the number of deaths by up to about 90% with high adherence. The drug was studied because of its anti-inflammatory effects, but the mechanism of action against COVID-19 remains uncertain.[33] [34] [35]

On 16 December, the NIH found that use of fluvoxamine did not impact incidence of covid-related hospitalizations and considered the evidence insufficient to recommend either for or against the drug.[36]

On 23 December, under very low certainty evidence, the Ontario clinical practice guideline suggested considering the drug to treat mildly ill patients within 7 days of symptom onset.[37]

In May 2022, based on a review of available scientific evidence, the US Food and Drug Administration (FDA) declined a request to issue an Emergency Use Authorization (EUA) for fluvoxamine to treat COVID-19, saying that the data were not sufficient to conclude that it may be effective in treating non-hospitalized people with COVID-19 to prevent serious illness or hospitalization. University of Minnesota professor David Boulware, who filed the EUA application, said that the standard that they were holding for fluvoxamine was a different standard than the other big pharma trials, with Paxlovid and molnupiravir and the monoclonals.[38] [39]

Antioxidants

Acetylcysteine (NAC)

Acetylcysteine is being considered as a possible treatment for COVID-19.[40]

Antiparasitics

The idea of repurposing host-directed drugs for antiviral therapy has experienced a renaissance.[41] In some cases the research has highlighted fundamental limitations to their use for the treatment of acute RNA virus infections.[42] Antiparasitics that have been investigated include chloroquine,[43] hydroxychloroquine,[44] mefloquine,[45] [46] ivermectin,[47] and atovaquone.[48]

Ivermectin

Antivirals

Research is focused on repurposing approved antiviral drugs that have been previously developed against other viruses, such as MERS-CoV, SARS-CoV, and West Nile virus.[49] These include favipiravir, remdesivir,[50] ribavirin,[51] triazavirin,[52] and umifenovir.[53]

The combination of artesunate/pyronaridine was found to have an inhibitory effect on SARS-CoV-2 in vitro tests using Hela cells. Artesunate/pyronaridine showed a virus titer inhibition rate of 99% or more after 24 hours, while cytotoxicity was also reduced.[54] A preprint published in July 2020, reported that pyronaridine and artesunate exhibit antiviral activity against SARS-CoV-2 and influenza viruses using human lung epithelial (Calu-3) cells.[55] It is in phase II clinical trial in South Korea[56] [57] [58] and in South Africa.[59]

Molnupiravir is a drug developed to treat influenza. It is in Phase III trials as a treatment for COVID-19.[60] [61] [62] [63] [64] In December 2020, scientists reported that the antiviral drug molnupiravir developed for the treatment of influenza can completely suppress SARS-CoV-2 transmission within 24 hours in ferrets whose COVID-19 transmission they find to closely resemble SARS-CoV-2 spread in human young-adult populations.[65] [66] A clinical trial, which has not as of 1 October 2021 been peer reviewed, suggests molnupiravir taken orally can reduce the risk of hospitalization and prevent death in patients diagnosed with COVID-19. The drug needs to be given early to be effective.[67] [68] As of 1 January 2022, Molnupiravir has been approved for emergency use against COVID-19 in the United Kingdom, India, and the United States.[69]

Niclosamide was identified as a candidate antiviral in an in vitro drug screening assay done in South Korea.[70]

Protease inhibitors, which specifically target the protease 3CLpro, are being researched and developed in the laboratory such as CLpro-1, GC376, and Rupintrivir.[71] [72] [73]

Coronaviruses species possess an intrinsic resistance to ribavirin.[74]

Sofosbuvir/daclatasvir is a drug combination developed to treat hepatitis C. In October 2020, a meta-analysis found a significantly lower risk of all-cause mortality with the drug combination when given to hospitalized patients.[75]

Favipiravir

Favipiravir is an antiviral drug approved for the treatment of influenza in Japan.[76] There is limited evidence suggesting that, compared to other antiviral drugs, favipiravir might improve outcomes for people with COVID-19, but more rigorous studies are needed before any conclusions can be drawn.[77]

Chinese clinical trials in Wuhan and Shenzhen claimed to show that favipiravir was "clearly effective".[78] Of 35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.[79] In a study conducted in Wuhan on 240 patients with pneumonia half were given favipiravir and half received umifenovir. The researchers found that patients recovered from coughs and fevers faster when treated with favipiravir, but that there was no change in how many patients in each group progressed to more advanced stages of illness that required treatment with a ventilator.[80]

On 22 March 2020, Italy approved the drug for experimental use against COVID-19 and began conducting trials in the three regions most affected by the disease.[81] The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.[82]

On 30 May 2020, the Russian Health Ministry approved a generic version of favipiravir named Avifavir, which proved highly effective in the first phase of clinical trials.[83] [84] [85]

In June 2020, India approved the use of a generic version of favipravir called FabiFlu, developed by Glenmark Pharmaceuticals, in the treatment of mild to moderate cases of COVID-19.[86]

On 26 May 2021, a systematic review found a 24% greater chance of clinical improvement when administered in the first seven days of hospitalization, but no statistically significant reduction in mortality for any of the groups, including hospitalized patients and those with mild or moderate symptoms.[87] [88]

Lopinavir/ritonavir

In March 2020, the main protease (3CLpro) of the SARS-CoV-2 virus was identified as a target for post-infection drugs. The enzyme is essential for processing the replication-related polyprotein. To find the enzyme, scientists used the genome published by Chinese researchers in January 2020 to isolate the main protease.[89] Protease inhibitors approved for treating human immunodeficiency viruses (HIV) – lopinavir and ritonavir – have preliminary evidence of activity against the coronaviruses, SARS and MERS.[7] [90] As a potential combination therapy, they are used together in two Phase III arms of the 2020 global Solidarity project on COVID-19.[91] A preliminary study in China of combined lopinavir and ritonavir found no effect in people hospitalized for COVID-19.[92]

One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".[93] The drugs were designed to inhibit HIV from replicating by binding to the protease. A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.[94] There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS because such drugs are unlikely to be effective against a virus lacking the specific HIV-1 protease they target. The WHO included lopinavir/ritonavir in the international Solidarity trial.[95]

On 29 June, the chief investigators of the UK RECOVERY Trial reported that there was no clinical benefit from use of lopinavir-ritonavir in 1,596 people hospitalized with severe COVID-19 infection over 28 days of treatment.[96] [97]

A study published in October 2020, screening those drugs approved by the US Food and Drug Administration (FDA) which target SARS-CoV-2 spike (S) protein proposed that the current unbalanced combination formula of lopinavir might in fact interfere with the ritonavir's blocking activity on the receptor binding domain-human angiotensin converting enzyme-2 (RBD-hACE2) interaction, thus effectively limiting its therapeutic benefit in COVID-19 cases.[98]

In 2022, the PANORAMIC trial is testing the effectiveness of nirmatrelvir combined with ritonavir, and molnupiravir in preventing hospitalization and helping faster recovery for people aged over 50 and those at higher risk due to underlying health conditions.[99] [100] As of March 2022 has over 16,000 people enrolled as participants making it the largest study into COVID-19 antivirals.[101]

Remdesivir

Immunomodulatory treatments

Baricitinib

In May 2022, the US Food and Drug Administration (FDA) approved barictinib for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).[102] Barictinib is the first immunomodulatory treatment for COVID-19 to receive FDA approval.

In the United States, barictinib is authorized under an emergency use authorization (EUA) for the treatment of COVID-19 in hospitalized people aged 2 to less than 18 years of age who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.[103]

Immunosuppressants

Anakinra

In December 2021, anakinra (Kineret) was authorized in the European Union for the treatment of COVID-19 in adults with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure, as determined by blood levels of a protein called suPAR (soluble urokinase plasminogen activator receptor) of at least 6 ng per ml."[104] [105]

Interferons

Drugs with immune modulating effects that may prove useful in COVID-19 treatment include type I Interferons such as Interferon-β, peginterferon alpha-2a and -2b.[106] [107]

IFN-β 1b have been shown in an open label randomised controlled trial in combination with lopinavir/ ritonavir and ribavirin to significantly reduce viral load, alleviate symptoms and reduce cytokine responses when compared to lopinavir/ ritonavir alone. IFN-β will be included in the international Solidarity Trial in combination with the HIV drugs Lopinavir and Ritonavir. as well as the REMAP-CAP Finnish biotech firm Faron Pharmaceuticals continues to develop INF-beta for ARDS and is involved in worldwide initiatives against COVID-19, including the Solidarity trial.[108] UK biotech firm Synairgen started conducting trials on IFN-β, a drug that was originally developed to treat COPD.

Steroids

Systemic corticosteroids have a small but statistically significant beneficial effect in reducing 30-day all-cause mortality in individuals hospitalized with COVID-19.[109]

Budesonide

Administration of this inhaled steroid early in the course of COVID-19 infection has been found to reduce the likelihood of needing urgent medical care and reduced the time to recovery.[110] [111] More studies are on-going.[111] In April 2021, budesonide was approved by authorities in the UK for off-label use to treat COVID-19 on a case-by-case basis.[112]

Ciclesonide

Ciclesonide, an inhaled corticosteroid for asthma, was identified as a candidate antiviral in an in vitro drug screening assay done in South Korea. It has been used for treatment of pre-symptomatic COVID-19 patients and is undergoing clinical trials.[113]

Dexamethasone

Dexamethasone is a corticosteroid medication in use for multiple conditions such as rheumatic problems, skin diseases, asthma and chronic obstructive lung disease among others.[114] A multi-center, randomized controlled trial of dexamethasone in treating acute respiratory distress syndrome (ARDS), published in February 2020, showed reduced need for mechanical ventilation and mortality.[115] Dexamethasone is only helpful in people requiring supplemental oxygen. Following an analysis of seven randomized trials,[116] the WHO recommends the use of systemic corticosteroids in guidelines for treatment of people with severe or critical illness, and that they not be used in people that do not meet the criteria for severe illness.[117]

On 16 June, the Oxford University RECOVERY Trial issued a press release announcing preliminary results that the drug could reduce deaths by about a third in participants on ventilators and by about a fifth in participants on oxygen; it did not benefit patients who did not require respiratory support. The researchers estimated that treating 8 patients on ventilators with dexamethasone saved one life, and treating 25 patients on oxygen saved one life.[118] Several experts called for the full dataset to be published quickly to allow wider analysis of the results.[119] [120] A preprint was published on 22 June[121] and the peer-reviewed article appeared on 17 July.[122]

Based on those preliminary results, dexamethasone treatment has been recommended by the US National Institutes of Health (NIH) for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but are not mechanically ventilated. The NIH recommends against using dexamethasone in patients with COVID-19 who do not require supplemental oxygen.[123] In July 2020, the World Health Organization (WHO) stated they are in the process of updating treatment guidelines to include dexamethasone or other steroids.[124]

The Infectious Diseases Society of America (IDSA) guideline panel suggests the use of glucocorticoids for patients with severe COVID-19; where severe is defined as patients with oxygen saturation (SpO2) ≤94% on room air, and those who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).[125] The IDSA recommends against the use of glucocorticoids for those with COVID-19 without hypoxemia requiring supplemental oxygen.

In July 2020, the European Medicines Agency (EMA) started reviewing results from the RECOVERY study arm that involved the use of dexamethasone in the treatment of patients with COVID-19 admitted to the hospital to provide an opinion on the results. It focused particularly on the potential use of the drug for the treatment of adults with COVID-19.[126]

In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19.[127] [128] The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID-19 (strong recommendation, based on moderate certainty evidence). The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID-19 (conditional recommendation, based on low certainty evidence).

In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents (from twelve years of age and weighing at least 40kg (90lb)) who require supplemental oxygen therapy.[129] Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.

Hydrocortisone

In September 2020, a meta-analysis published by the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group found hydrocortisone to be effective in reducing mortality rate of critically ill COVID-19 patients when compared to other usual care or a placebo.[130]

The use of corticosteroids can cause a severe and deadly "hyperinfection" syndrome for people with strongyloidiasis, which may be an underlying condition in populations exposed to the parasite Strongyloides stercoralis. This risk can be mitigated by the presumptive use of ivermectin before steroid treatment.[131]

Methylprednisolone

In March–April 2020, a small bioinformatics company, AdvaitaBio, used its data analysis platform, iPathwayGuide, to analyze one of the first transcriptomics data sets that became available from COVID-19 patients.[132] This analysis was able to identify methylprednisolone as a drug that could potentially help patients with severe cases of this disease. The analysis of the molecular data indicated that patients with severe COVID-19 suffered from the cytokine storm syndrome, and also identified the specific pathways and mechanisms through which methylprednisolone would help revert many of the important gene expression changes induced by the cytokine storm.[133] A subsequent clinical trial undertaken in the Henry Ford Health Systems showed that methylprednisolone reduced mortality by approximately 44% (from 29.6% to 16.6%).[134] The results contradicted flagrantly the recommendations of the World Health Organization, which at the time, had a standing recommendation NOT to use systemic steroids in COVID-19 patients.[135] This, together with the very tense scientific environment cause by theretraction of some early COVID-19-related papers,[136] delayed the publication of these results by several months. This was very unfortunate, since methylprednisolone is low-cost and widely available and could have prevented many thousands of deaths. Several months later, the results of the RECOVERY trial (see dexamethasone above) also showed steroids as being effective in reducing mortality, and helped change the general opinion about steroid treatments in COVID-19. The drug repurposing analysis that was first to propose a steroid for severe COVID-19 case was eventually published in the journal Bioinformatics Currently, steroids including methylprednisolone and dexamethasone are part of the standard of care in severe cases of COVID-19.

For a composite end point of preventing ICU admission, need for mechanical ventilator or mortality, the number needed to treat (NNT) to benefit a single patient was only 5 for methylprednisolone when used early in hospitalization. The NNT necessary for methylprednisolone to avoid a death was only 8 for all hospitalized patients. This is in contrast to the RECOVERY trial (NCT04323592) for dexamethasone (see Dexamethasone above), where NNT was 8 for patients on mechanical ventilation, and 25 for patients needed oxygen to prevent mortality.

Vitamins

Vitamin C

Supplementation with vitamin C, has been suggested as part of the supportive management of COVID-19, as serum levels of the vitamin are depleted in the acute stage of infection owing to increased metabolic demands.[137] In April 2021, the US National Institutes of Health (NIH) COVID-19 Treatment Guidelines stated that "there are insufficient data to recommend either for or against the use of vitaminC for the prevention or treatment of COVID-19."[138] In an update posted December 2022, the NIH position was unchanged:

Three meta-analyses of people hospitalized with severe COVID-19 - with a high overlap in the clinical trials being included - reported a significant reduction in the risk of all-cause, in-hospital mortality with the administration of vitamin C relative to no vitamin C. There were no significant differences in ventilation incidence, hospitalization duration or length of intensive care unit stay between the two groups. The majority of the trials used intravenous administration of the vitamin.[140] [141] [142] Acute kidney injury was lower in people treated with vitamin C treatment. There were no differences in the frequency of other adverse events due to the vitamin. All three journal articles concluded that further large-scale studies are needed to affirm its mortality benefits before issuing updated guidelines and recommendations.

Vitamin D

During the COVID-19 pandemic, there has been interest in vitaminD status and supplements, given the significant overlap in the risk factors for severe COVID-19 and vitaminD deficiency.[143] These include obesity, older age, and Black or Asian ethnic origin, and it is notable that vitaminD deficiency is particularly common within these groups.[143]

The National Institutes of Health (NIH) COVID-19 Treatment Guidelines states "there is insufficient evidence to recommend either for or against the use of vitamin D for the prevention or treatment of COVID-19."[144]

The general recommendation to consider taking vitamin D supplements, particularly given the levels of vitamin D deficiency in Western populations, has been repeated.[145], the English National Institute for Health and Care Excellence (NICE) continued to recommend small doses of supplementary vitaminD for people with little exposure to sunshine, but recommended that practitioners should not offer a vitaminD supplement solely to prevent or treat COVID-19, except as part of a clinical trial.

Multiple studies have reported links between pre-existing vitamin D deficiency and the severity of the disease. Several systematic reviews and meta-analyses of these show that vitamin D deficiency may be associated with a higher probability of becoming infected with COVID-19, and have clearly demonstrated there are significant associations between deficiency and a greater severity of the disease, including relative increases in hospitalization and mortality rates of about 80%.[146] [147] [148] The quality of some of the studies included and whether this demonstrates a causal relationship has been questioned.[149]

Many clinical trials are underway or have been completed assessing the use of oral vitaminD and its metabolites such as calcifediol for prevention or treatment of COVID-19 infection, especially in people with vitamin D deficiency.[150] [151] [152]

The effects of oral vitamin D supplementation on the need for intensive care unit (ICU) admission and mortality in hospitalized COVID-19 patients has been the subject of a meta-analysis.[153] A much lower ICU admission rate was found in patients who received vitamin D supplementation, which was only 36% of that seen in patients without supplementation (p<0.0001).[153] No significant effects on mortality were found in this meta-analysis.[153] The certainty of these analyses is limited by the heterogenicity in the studies which include both vitamin D3 (cholecalciferol) and calcifediol, but these findings indicate a potential role in improving COVID-19 severity, with more robust data being required to substantiate any effects on mortality.[153] [154]

Calcifediol, which is 25-hydroxyvitamin D, is more quickly activated,[155] and has been used in several trials.[151] Review of the published results suggests that calcifediol supplementation may have a protective effect on the risk of ICU admissions in COVID-19 patients.[149]

Minerals

Zinc

The National Institutes of Health (NIH) COVID-19 Treatment Guidelines states "there is insufficient evidence to recommend either for or against the use of zinc for the treatment of COVID-19" and that "the Panel recommends against using zinc supplementation above the recommended dietary allowance for the prevention of COVID-19, except in a clinical trial (BIII)."[156]

Others

Found ineffective

The use of aspirin, hydroxychloroquine,[182] azithromycin,[183] and colchicine were found ineffective against COVID-19. The use of the combination of lopinavir and ritonavir together was found ineffective against COVID-19.[184] The use of the combination of etesevimab and bamlanivimab together was found ineffective against the Omicron variant.[184]

Further reading

External links

Notes and References

  1. Web site: Repurposing Drugs . 7 November 2017 . 26 March 2020 . National Center for Advancing Translational Sciences (NCATS) . U.S. Department of Health & Human Services, National Institutes of Health . 4 October 2020 . https://web.archive.org/web/20201004122507/https://ncats.nih.gov/preclinical/repurpose . live .
  2. Harrison C . Coronavirus puts drug repurposing on the fast track . Nature Biotechnology . 38 . 4 . 379–381 . April 2020 . 32205870 . 10.1038/d41587-020-00003-1 . 213394680 . free .
  3. MacRaild CA, Mohammed MU, Murugesan S, Styles IK, Peterson AL, Kirkpatrick CM, Cooper MA, Palombo EA, Simpson MM, Jain HA, Agarwal V, McAuley AJ, Kumar A, Creek DJ, Trevaskis NL, Vasan SS . Systematic Down-Selection of Repurposed Drug Candidates for COVID-19 . International Journal of Molecular Sciences . 23 . 19 . 11851 . October 2022 . 36233149 . 9569752 . 10.3390/ijms231911851 . free .
  4. Sleigh SH, Barton CL . 10.1007/BF03256811. Repurposing Strategies for Therapeutics. 2010 . Pharmaceutical Medicine. 24. 3. 151–59. 25267555.
  5. Web site: COVID-19 Vaccine Frontrunners . 16 April 2020 . 6 May 2020 . https://web.archive.org/web/20200506041249/https://www.the-scientist.com/news-opinion/covid-19-vaccine-frontrunners-67382 . live .
  6. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X . Effectiveness of convalescent plasma therapy in severe COVID-19 patients . Proceedings of the National Academy of Sciences of the United States of America . 117 . 17 . 9490–9496 . April 2020 . 32253318 . 7196837 . 10.1073/pnas.2004168117 . free . 2020PNAS..117.9490D .
  7. Li G, De Clercq E . Therapeutic options for the 2019 novel coronavirus (2019-nCoV) . Nature Reviews. Drug Discovery . 19 . 3 . 149–150 . March 2020 . 32127666 . 10.1038/d41573-020-00016-0 . free .
  8. Web site: COVID-19 treatment and vaccines tracker (Choose tab of interest, apply filters to view select data) . Milken Institute . 3 June 2020 . 2 June 2020 . 3 June 2020 . https://web.archive.org/web/20200603161548/https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=hide . live .
  9. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB . Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review . JAMA . 323 . 18 . 1824–1836 . May 2020 . 32282022 . 10.1001/jama.2020.6019 . free .
  10. Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK . Drug repurposing approach to fight COVID-19 . Pharmacological Reports . 72 . 6 . 1479–1508 . December 2020 . 32889701 . 7474498 . 10.1007/s43440-020-00155-6 .
  11. News: Zimmer C . How the Search for Covid-19 Treatments Faltered While Vaccines Sped Ahead . . 30 January 2021 . 15 November 2021 . 15 November 2021 . https://web.archive.org/web/20211115192045/https://www.nytimes.com/2021/01/30/health/covid-drugs-antivirals.html . live .
  12. Kirtonia A, Gala K, Fernandes SG, Pandya G, Pandey AK, Sethi G, Khattar E, Garg M . Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics . Seminars in Cancer Biology . 68 . 258–278 . January 2021 . 32380233 . 10.1016/j.semcancer.2020.04.006 . 218556384 .
  13. Carbone M, Lednicky J, Xiao SY, Venditti M, Bucci E . Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For . Journal of Thoracic Oncology . 16 . 4 . 546–571 . April 2021 . 33422679 . 7832772 . 10.1016/j.jtho.2020.12.014 .
  14. Mule S, Singh A, Greish K, Sahebkar A, Kesharwani P, Shukla R . Drug repurposing strategies and key challenges for COVID-19 management . Journal of Drug Targeting . 30 . 4 . 413–429 . April 2022 . 34854327 . 10.1080/1061186X.2021.2013852 . 244863256 .
  15. Maziarz M, Stencel A . The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence . History and Philosophy of the Life Sciences . 44 . 4 . 47 . October 2022 . 36258007 . 9579070 . 10.1007/s40656-022-00532-9 .
  16. Adashek JJ, Kurzrock R . Balancing clinical evidence in the context of a pandemic . Nature Biotechnology . 39 . 3 . 270–274 . March 2021 . 33547424 . 10.1038/s41587-021-00834-6 . 232217402 . free .
  17. Web site: RECOVERY Trial. 17 June 2020. 12 October 2020. https://web.archive.org/web/20201012051340/https://www.recoverytrial.net/. live.
  18. Web site: Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. 10 September 2020. ClinicalTrials.gov. 12 June 2022. https://web.archive.org/web/20220612044958/https://clinicaltrials.gov/ct2/show/NCT04347226. live.
  19. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab. https://web.archive.org/web/20120928202943/http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf. 28 September 2012. American Medical Association.
  20. Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F . Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study . Annals of the Rheumatic Diseases . 70 . 9 . 1542–1549 . September 2011 . 21613310 . 3147227 . 10.1136/ard.2010.146225 .
  21. De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, Boffini N, Tentori S, Mette F, Farina N, Rovere-Querini P, Ruggeri A, D'Aliberti T, Scarpellini P, Landoni G, De Cobelli F, Paolini JF, Zangrillo A, Tresoldi M, Trapnell BC, Ciceri F, Dagna L . GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study . The Lancet. Rheumatology . 2 . 8 . e465–e473 . August 2020 . 32835256 . 7430344 . 10.1016/S2665-9913(20)30170-3 . doi . free .
  22. Web site: 7 January 2021. Arthritis drugs effective in improving survival in sickest COVID-19 patients. National Institute for Health Research. 21 February 2021. 25 January 2021. https://web.archive.org/web/20210125172954/https://www.nihr.ac.uk/news/arthritis-drugs-effective-in-improving-survival-in-sickest-covid-19-patients/26535. live.
  23. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy . Journal of Thrombosis and Haemostasis . 18 . 5 . 1094–1099 . May 2020 . 32220112 . 9906401 . 10.1111/jth.14817 . doi . free .
  24. Web site: Medicines usable for treatment of COVID-19 disease. 29 March 2021. Italian Medicines Agency. 15 April 2021. https://web.archive.org/web/20210415152156/https://www.aifa.gov.it/en/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19. live.
  25. Web site: Low molecular weight heparins in the treatment of adult patients with COVID-19 . 24 November 2020 . AIFA Italian Medicines Agencty . 30 March 2021 . 27 August 2021 . https://web.archive.org/web/20210827020958/https://www.aifa.gov.it/documents/20142/1267737/Low-molecular-weight-heparins_EN_24.11.2020.pdf/fc92d837-e27a-17af-18db-9a8635fb19d5 . live .
  26. News: Weintraub A. How COVID-19 could be crippled by an age-old blood thinner. 22 July 2020. Fierce Biotech. 20 July 2020. 22 July 2020. https://web.archive.org/web/20200722054718/https://www.fiercebiotech.com/research/how-covid-19-could-be-crippled-by-age-old-blood-thinner. live.
  27. Web site: Coronavirus, al via studio su eparina per 300 pazienti. 15 April 2020. Adnkronos. 6 October 2020. https://web.archive.org/web/20201006215007/https://www.adnkronos.com/fatti/cronaca/2020/04/14/coronavirus-via-studio-eparina-per-pazienti_HrgtSshZ2QAWLr3CLN2dpM.html/. live.
  28. Rogosnitzky M, Berkowitz E, Jadad AR . Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point . JMIR Public Health and Surveillance . 6 . 2 . e19199 . May 2020 . 32374264 . 7224168 . 10.2196/19199 . free .
  29. Web site: Chinese Clinical Trial Register (ChiCTR) – The world health organization international clinical trials registered organization registered platform. www.chictr.org.cn. 30 April 2020. 6 October 2020. https://web.archive.org/web/20201006215122/http://www.chictr.org.cn/showprojen.aspx?proj=49864%2F. live.
  30. News: Landhuis E . Investigating Antidepressants' Surprising Effect on COVID Deaths . 1 December 2021 . Scientific American . 12 November 2021 . 1 December 2021 . https://web.archive.org/web/20211201100346/https://www.scientificamerican.com/article/investigating-antidepressants-surprising-effect-on-covid-deaths/ . live .
  31. Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, Salamanca E, Paris N, Daniel C, Gramfort A, Lemaitre G, Bernaux M, Bellamine A, Lemogne C, Airagnes G, Burgun A, Limosin F . Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study . Molecular Psychiatry . 26 . 9 . 5199–5212 . September 2021 . 33536545 . 10.1038/s41380-021-01021-4 . 231794088 . free .
  32. Mahdi M, Hermán L, Réthelyi JM, Bálint BL . Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19 . International Journal of Molecular Sciences . 23 . 7 . 3812 . March 2022 . 35409171 . 8998734 . 10.3390/ijms23073812 . free .
  33. Sidik SM . Common antidepressant slashes risk of COVID death, study says . Nature . October 2021 . 34716441 . 10.1038/d41586-021-02988-4 . 240229837 .
  34. News: Fox M . Cheap, generic anti-depressant may reduce severe Covid-19 disease, study finds . 22 November 2021 . CNN . 28 October 2021 . 22 November 2021 . https://web.archive.org/web/20211122141820/https://edition.cnn.com/2021/10/28/health/fluvoxamine-covid-risk-study/index.html . live .
  35. Reis G, Dos Santos Moreira-Silva EA, Silva DC, Thabane L, Milagres AC, Ferreira TS, Dos Santos CV, de Souza Campos VH, Nogueira AM, de Almeida AP, Callegari ED, de Figueiredo Neto AD, Savassi LC, Simplicio MI, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ . Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial . The Lancet. Global Health . 10 . 1 . e42–e51 . January 2022 . 34717820 . 8550952 . 10.1016/S2214-109X(21)00448-4 .
  36. Web site: Fluvoxamine Clinical Data . 7 February 2022 . COVID-19 Treatment Guidelines . 16 December 2022 . 26 January 2022 . https://web.archive.org/web/20220126151351/https://www.covid19treatmentguidelines.nih.gov/tables/fluvoxamine-data/ . live .
  37. Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group . Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 . Version 6.0 . 23 December 2021 . Ontario COVID-19 Science Advisory Table . 10.47326/ocsat.cpg.2021.6.0 . 245441405 . 24 December 2021 . 24 December 2021 . https://web.archive.org/web/20211224124945/https://covid19-sciencetable.ca/sciencebrief/clinical-practice-guideline-summary-recommended-drugs-and-biologics-in-adult-patients-with-covid-19-version-6-0/ . live . free .
  38. News: FDA declines to authorize common antidepressant as COVID treatment . 18 May 2022 . Reuters . 16 May 2022 . 17 May 2022 . https://web.archive.org/web/20220517202625/https://www.reuters.com/business/healthcare-pharmaceuticals/fda-declines-authorize-common-antidepressant-covid-treatment-2022-05-16/ . live .
  39. Memorandum . Memorandum Explaining Basis for Declining Request for Emergency Use Authorization of Fluvoxamine Maleate . 4975580 . Food and Drug Administration . 16 May 2022 . https://web.archive.org/web/20220517001646/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/EUA%20110%20Fluvoxamine%20Decisional%20Memo_Redacted.pdf . 17 May 2022 . live.
  40. News: N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence. 20 February 2022. 20 February 2022. https://web.archive.org/web/20220220051824/https://www.dovepress.com/n-acetylcysteine-as-adjuvant-therapy-for-covid-19--a-perspective-on-th-peer-reviewed-fulltext-article-JIR. live.
  41. Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M . Host-directed therapies for infectious diseases: current status, recent progress, and future prospects . The Lancet. Infectious Diseases . 16 . 4 . e47–e63 . April 2016 . 27036359 . 7164794 . 10.1016/S1473-3099(16)00078-5 . review .
  42. Sourimant J, Aggarwal M, Plemper RK . Progress and pitfalls of a year of drug repurposing screens against COVID-19 . Current Opinion in Virology . 49 . 183–193 . August 2021 . 34218010 . 8214175 . 10.1016/j.coviro.2021.06.004 .
  43. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro . Cell Research . 30 . 3 . 269–271 . March 2020 . 32020029 . 7054408 . 10.1038/s41422-020-0282-0 .
  44. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D . Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial . International Journal of Antimicrobial Agents . 56 . 1 . 105949 . July 2020 . 32205204 . 7102549 . 10.1016/j.ijantimicag.2020.105949 .
  45. Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, Reyes HM, Weiss SR, Frieman MB . Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo . Journal of Virology . 94 . 21 . October 2020 . 32817221 . 7565640 . 10.1128/JVI.01218-20 . doi . free .
  46. Web site: ФМБА России: доказана противовирусная активность "Мефлохина" в отношении возбудителя COVID-19. 10 April 2020. Federal Biomedical Agency. ru. 11 April 2020. 11 April 2020. https://web.archive.org/web/20200411152641/http://fmbaros.ru/press-tsentr/novosti/detail/?ELEMENT_ID=38239. dead.
  47. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM . The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro . Antiviral Research . 178 . 104787 . June 2020 . 32251768 . 7129059 . 10.1016/j.antiviral.2020.104787 .
  48. Web site: Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection . ClinicalTrials.gov . 10 September 2020 . 24 November 2020 . https://web.archive.org/web/20201124192133/https://clinicaltrials.gov/ct2/show/NCT04339426 . live .
  49. Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19) . Drug Discoveries & Therapeutics . 14 . 1 . 58–60 . 2020 . 32147628 . 10.5582/ddt.2020.01012 . free .
  50. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial . Lancet . 395 . 10236 . 1569–1578 . May 2020 . 32423584 . 7190303 . 10.1016/S0140-6736(20)31022-9 .
  51. Lu CC, Chen MY, Lee WS, Chang YL . Potential therapeutic agents against COVID-19: What we know so far . Journal of the Chinese Medical Association . 83 . 6 . 534–536 . June 2020 . 32243270 . 7176266 . 10.1097/JCMA.0000000000000318 .
  52. Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Zhao M, Zhang Y, Li K, Du Z, Yang B . The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol . Engineering . 6 . 10 . 1199–1204 . October 2020 . 32837750 . 7332434 . 10.1016/j.eng.2020.06.011 . 2020Engin...6.1199W .
  53. Lu H . Drug treatment options for the 2019-new coronavirus (2019-nCoV) . BioScience Trends . 14 . 1 . 69–71 . March 2020 . 31996494 . 10.5582/bst.2020.01020 . free .
  54. News: 'Pyramax' drug repurposing?... targets COVID-19 treatment. Doctor's News. 25 June 2020. 26 June 2020. https://web.archive.org/web/20200626195039/http://www.doctorsnews.co.kr/news/articleView.html?idxno=134131. live.
  55. Bae JY, Lee GE, Park H, Cho J, Kim YE, Lee JY, Ju C, Kim WK, Kim JI, Park MS . 2020. Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza. 10.1101/2020.07.28.225102. bioRxiv. 220885187.
  56. News: COVID-19: Pyramax Enters Phase II Clinical Trial in South Korea. www.pharmanewsonline.com. 17 June 2020. 18 August 2020. https://web.archive.org/web/20200818053947/https://www.pharmanewsonline.com/covid-19-pyramax-enters-phase-ii-clinical-trial-in-south-korea/. live.
  57. Web site: A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase II Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients. 25 June 2020. nedrug.mfds.go.kr. 6 October 2020. https://web.archive.org/web/20201006215038/https://nedrug.mfds.go.kr/pbp/CCBBC01/nexacroPageOpen?approvalDtStart=2020-05-13&searchType=ST1&searchYn=true&localList=000&page=1&approvalDtEnd=2020-05-13&&clinicExamSeq=202000349&clinicExamNo=32878&receiptNo=20200091140&approvalDt=2020-05-13%2F. live.
  58. Web site: The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients. 10 September 2020. ClinicalTrials.gov. 6 October 2020. https://web.archive.org/web/20201006215028/https://clinicaltrials.gov/ct2/show/NCT04475107/. live.
  59. Web site: COVID-19 Treatment in South Africa. 21 September 2020. ClinicalTrials.gov. 6 October 2020. https://web.archive.org/web/20201006215020/https://clinicaltrials.gov/ct2/show/NCT04532931/. live.
  60. Web site: Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) . ClinicalTrials.gov . 25 June 2021 . 18 October 2021 . 19 October 2021 . https://web.archive.org/web/20211019025012/https://clinicaltrials.gov/ct2/show/NCT04939428 . live .
  61. Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) . ClinicalTrials.gov . 5 October 2020 . 18 October 2021 . 19 October 2021 . https://web.archive.org/web/20211019025013/https://clinicaltrials.gov/ct2/show/NCT04575584 . live .
  62. Web site: Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) . ClinicalTrials.gov . 5 October 2020 . 18 October 2021 . 18 October 2021 . https://web.archive.org/web/20211018215210/https://www.clinicaltrials.gov/ct2/show/NCT04575597 . live .
  63. Web site: A Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19. 10 September 2020. ClinicalTrials.gov. 15 September 2020. https://web.archive.org/web/20200915011556/https://www.clinicaltrials.gov/ct2/show/NCT04405570. live.
  64. Web site: The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID). 10 September 2020. ClinicalTrials.gov. 10 September 2020. https://web.archive.org/web/20200910121456/https://www.clinicaltrials.gov/ct2/show/NCT04405739. live.
  65. News: Oral drug blocks SARS-CoV-2 transmission. medicalxpress.com. 16 January 2021. 16 January 2021. https://web.archive.org/web/20210116214211/https://medicalxpress.com/news/2020-12-oral-drug-blocks-sars-cov-transmission.html. live.
  66. Cox RM, Wolf JD, Plemper RK . Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets . Nature Microbiology . 6 . 1 . 11–18 . January 2021 . 33273742 . 7755744 . 10.1038/s41564-020-00835-2 . doi . free .
  67. https://www.bbc.co.uk/news/health-58764440 Covid antiviral pill can halve risk of hospitalisation
  68. https://www.theguardian.com/world/2021/oct/01/covid-antiviral-pill-halves-hospitalisations-and-deaths-maker-says Covid antiviral pill halves hospitalisations and deaths, maker says
  69. News: Molnupiravir gets nod for emergency use in India: From how it works to countries who approved it, everything about antiviral pill . 2 January 2022 . Financial Express . 29 December 2022 . 2 January 2022 . https://web.archive.org/web/20220102035708/https://www.financialexpress.com/lifestyle/health/molnupiravir-gets-nod-for-emergency-use-in-india-from-how-it-works-to-countries-who-approved-it-everything-about-antiviral-pill/2392910/ . live .
  70. Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S . Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs . Antimicrobial Agents and Chemotherapy . 64 . 7 . June 2020 . 32366720 . 7318052 . 10.1128/AAC.00819-20 .
  71. Morse JS, Lalonde T, Xu S, Liu WR . Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV . ChemBioChem . 21 . 5 . 730–738 . March 2020 . 32022370 . 7162020 . 10.1002/cbic.202000047 .
  72. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Smoot J, Gregg AC, Daniels AD, Jervey S, Albaiu D . Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases . ACS Central Science . 6 . 3 . 315–331 . March 2020 . 32226821 . 7094090 . 10.1021/acscentsci.0c00272 . doi . free .
  73. Ramajayam R, Tan KP, Liang PH . Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery . Biochemical Society Transactions . 39 . 5 . 1371–1375 . October 2011 . 21936817 . 10.1042/BST0391371 . doi . free .
  74. Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW . SARS-CoV-2 Antiviral Therapy . Clinical Microbiology Reviews . 34 . 4 . e0010921 . December 2021 . 34319150 . 8404831 . 10.1128/CMR.00109-21 . 236472654 .
  75. Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, Abbaspour Kasgari H, Tirgar Fakheri H, Merat S, Hill A . Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis . The Journal of Antimicrobial Chemotherapy . 76 . 2 . 286–291 . January 2021 . 33063117 . 7665526 . 10.1093/jac/dkaa418 .
  76. Zhang Y, Tang LV . Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication . Journal of Proteome Research . 20 . 1 . 49–59 . January 2021 . 33347311 . 7770889 . 10.1021/acs.jproteome.0c00526 .
  77. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P . Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis . Virology Journal . 17 . 1 . 141 . September 2020 . 32972430 . 7512218 . 10.1186/s12985-020-01412-z . free .
  78. News: 18 March 2020. Japanese flu drug 'clearly effective' in treating coronavirus, says China. 23 March 2020. 11 October 2020. https://web.archive.org/web/20201011205711/https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china. live.
  79. News: Coronavirus: Japanese anti-viral drug effective in treating patients, Chinese official says. The Independent. 5 April 2020. 9 October 2020. https://web.archive.org/web/20201009085714/https://www.independent.co.uk/news/world/asia/coronavirus-treatment-anti-viral-drug-favipiravir-avigan-wuhan-china-a9408066.html. live.
  80. Web site: Which Covid-19 drugs work best?. MIT Technology Review. 5 April 2020. 5 April 2020. https://web.archive.org/web/20200405223852/https://www.technologyreview.com/s/615394/covid-19-coronavirus-best-drugs-in-treating-the-outbreak/. live.
  81. Web site: 22 March 2020. Coronavirus, il Veneto sperimenta l'antivirale giapponese Favipiravir. Ma l'Aifa: "Ci sono scarse evidenze scientifiche su efficacia". 23 March 2020. Il Fatto Quotidiano. it-IT. 14 July 2020. https://web.archive.org/web/20200714044833/https://www.ilfattoquotidiano.it/2020/03/22/coronavirus-il-veneto-sperimenta-lantivirale-giapponese-favipiravir-ma-laifa-ci-sono-scarse-evidenze-scientifiche-su-efficacia/5745426/. live.
  82. Web site: AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull'efficacia. 23 March 2020. aifa.gov.it. it-IT. 8 August 2020. https://web.archive.org/web/20200808145556/https://www.aifa.gov.it/-/aifa-precisa-uso-favipiravir-per-covid-19-non-autorizzato-in-europa-e-usa-scarse-evidenze-scientifiche-sull-efficacia. live.
  83. News: 30 May 2020. Russian Ministry of Health approves the first COVID-19 drug Avifavir produced by JV of RDIF and ChemRar. RDIF. 31 May 2020. 6 October 2020. https://web.archive.org/web/20201006214757/https://rdif.ru/Eng_fullNews/5220//. dead.
  84. News: 31 May 2020. Russian Health Ministry approves anti-coronavirus drug Avifavir. BNN Bloomberg. 31 May 2020. 9 October 2020. https://web.archive.org/web/20201009114104/https://www.bnnbloomberg.ca/russian-health-ministry-approves-anti-coronavirus-drug-avifavir-1.1443601. live.
  85. News: 30 May 2020. Russia plans coronavirus vaccine clinical trials in two weeks. Reuters. 31 May 2020. 31 October 2020. https://web.archive.org/web/20201031033925/https://www.reuters.com/article/uk-health-coronavirus-russia-cases/russia-plans-coronavirus-vaccine-clinical-trials-in-two-weeks-report-idUKKBN2360BE. live.
  86. News: 20 June 2020. Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet. India Today. 30 June 2020. 11 October 2020. https://web.archive.org/web/20201011092137/https://www.indiatoday.in/india/story/coronavirus-treatment-drug-glenmark-fabiflu-favipiravir-launch-india-rs-103-per-tablet-reduce-viral-load-1691066-2020-06-20. live.
  87. News: Swift R . Feast L . Fujifilm's Avigan shows no significant benefit on COVID-19 mortality: study . 25 April 2021 . Reuters . 18 February 2021 . Tokyo . 25 April 2021 . https://web.archive.org/web/20210425134045/https://www.reuters.com/article/us-health-coronavirus-fujifilm-avigan-idUSKBN2AI0SK . live .
  88. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R . The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials . Scientific Reports . 11 . 1 . 11022 . May 2021 . 34040117 . 8155021 . 10.1038/s41598-021-90551-6 . 2021NatSR..1111022H .
  89. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R . Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors . Science . 368 . 6489 . 409–412 . April 2020 . 32198291 . 7164518 . 10.1126/science.abb3405 . 2020Sci...368..409Z . doi . free .
  90. Kupferschmidt K, Cohen J. 22 March 2020. WHO launches global megatrial of the four most promising coronavirus treatments. Science Magazine. 10.1126/science.abb8497. 216325781. 27 March 2020. 14 September 2020. https://web.archive.org/web/20200914153130/https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments. live. subscription.
  91. Mullard A . Flooded by the torrent: the COVID-19 drug pipeline . Lancet . 395 . 10232 . 1245–1246 . April 2020 . 32305088 . 7162641 . 10.1016/S0140-6736(20)30894-1 .
  92. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 . The New England Journal of Medicine . 382 . 19 . 1787–1799 . May 2020 . 32187464 . 7121492 . 10.1056/nejmoa2001282 .
  93. Web site: 20 March 2020. Antiviral Drug Combo Ineffective Vs. Coronavirus. WebMD. 23 March 2020. 23 March 2020. https://web.archive.org/web/20200323193906/https://www.webmd.com/lung/news/20200320/antiviral-drug-combo-ineffective-vs-coronavirus. live.
  94. News: Brown J. 20 March 2020. Colorado researchers are racing to find an antiviral drug that could save people with the new coronavirus. 23 March 2020. 23 March 2020. https://web.archive.org/web/20200323193906/https://coloradosun.com/2020/03/20/antiviral-treatment-for-coronavirus/. live.
  95. News: Devlin H, Sample I. 19 March 2020. What are the prospects for a COVID-19 treatment?. The Guardian. 23 March 2020. 9 October 2020. https://web.archive.org/web/20201009131852/https://www.theguardian.com/science/2020/mar/19/prospects-treatment-coronavirus-drugs-vaccines. live.
  96. Web site: 29 June 2020 . No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in Recovery . Recovery Trial . 30 June 2020 . 6 October 2020 . https://web.archive.org/web/20201006214815/https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf . live .
  97. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . Lancet . 396 . 10259 . 1345–1352 . October 2020 . 33031764 . 7535623 . 10.1016/S0140-6736(20)32013-4 . 222135901 . Recovery Collaborative Group . Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, Palfreeman A, Raw J, Elmahi E, Prudon B, Green C, Carley S, Chadwick D, Davies M, Wise MP, Baillie JK, Chappell LC, Faust SN, Jaki T, Jefferey K, Lim WS, Montgomery A, Rowan K, Juszczak E, Haynes R, Landray MJ .
  98. Bagheri M, Niavarani A . Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding . Journal of Biomolecular Structure & Dynamics . 40 . 4 . 1597–1606 . March 2022 . 33030105 . 10.1080/07391102.2020.1830854 . 222217607 . doi . free .
  99. Web site: NIHR funds community COVID-19 antiviral trial . 16 March 2022 . www.nihr.ac.uk . 16 March 2022 . https://web.archive.org/web/20220316093913/https://www.nihr.ac.uk/news/nihr-funds-community-covid-19-antiviral-trial/29048 . live .
  100. News: 25 January 2022 . Thousands needed to try a new Covid antiviral treatment . BBC News . 16 March 2022 . 16 March 2022 . https://web.archive.org/web/20220316093906/https://www.bbc.com/news/health-60117313 . live .
  101. Web site: Pinching J . 22 February 2022 . PANORAMIC view of World's largest COVID study . 16 March 2022 . PharmaTimes . 18 March 2022 . https://web.archive.org/web/20220318143429/https://www.pharmatimes.com/news/panoramic_view_of_worlds_largest_covid_study_1388052 . live .
  102. FDA Roundup: May 10, 2022 . U.S. Food and Drug Administration (FDA) . 10 May 2022 . 10 May 2022 . 10 May 2022 . https://web.archive.org/web/20220510213836/https://www.fda.gov/news-events/press-announcements/fda-roundup-may-10-2022 . live .
  103. Web site: Frequently Asked Questions on Olumiant (Baricitinib) for the Treatment of COVID-19 . PDF . U.S. Food and Drug Administration (FDA) . 10 May 2022 . 10 May 2022 . 29 July 2021 . https://web.archive.org/web/20210729004058/https://www.fda.gov/media/143825/download . live .
  104. Web site: Kineret EPAR . . 17 September 2018 . 20 July 2021 . 21 July 2021 . https://web.archive.org/web/20210721022322/https://www.ema.europa.eu/en/medicines/human/EPAR/kineret . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  105. Web site: EMA recommends approval for use of Kineret in adults with COVID-19 . European Medicines Agency . 16 December 2021 . 2 March 2022 . 7 January 2022 . https://web.archive.org/web/20220107083718/https://www.ema.europa.eu/en/news/ema-recommends-approval-use-kineret-adults-covid-19 . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  106. News: 27 March 2020. WHO officials enroll first patients from Norway and Spain in 'historic' coronavirus drug trial. CNBC. 12 April 2020. 12 April 2020. https://web.archive.org/web/20200412145436/https://www.cnbc.com/2020/03/27/who-officials-enroll-first-patients-from-norway-and-spain-in-historic-coronavirus-drug-trial.html. live.
  107. Web site: REMAP-CAP Trial. REMAP-CAP. 8 May 2020. 12 May 2020. https://web.archive.org/web/20200512031301/https://www.remapcap.org/. live.
  108. Traumakine to be a part of WHO's Solidarity trial investigating potential COVID-19 treatments. Faron Pharmaceuticals. 27 April 2020. 8 May 2020. 12 June 2022. https://web.archive.org/web/20220612044957/https://www.faron.com/news-events/news-and-press-releases?rnsid=1387792&cid=2223. live.
  109. Wagner C, Griesel M, Mikolajewska A, Metzendorf MI, Fischer AL, Stegemann M, Spagl M, Nair AA, Daniel J, Fichtner F, Skoetz N . Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence . The Cochrane Database of Systematic Reviews . 2022 . 11 . CD014963 . November 2022 . 36385229 . 9670242 . 10.1002/14651858.CD014963.pub2 . 253578836 .
  110. Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K, Fox R, Binnian I, Glover V, Bright S, Butler C, Cane JL, Halner A, Matthews PC, Donnelly LE, Simpson JL, Baker JR, Fadai NT, Peterson S, Bengtsson T, Barnes PJ, Russell RE, Bafadhel M . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial . The Lancet. Respiratory Medicine . 9 . 7 . 763–772 . July 2021 . 33844996 . 8040526 . 10.1016/S2213-2600(21)00160-0 .
  111. Agusti A, Torres F, Faner R . Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 . The Lancet. Respiratory Medicine . 9 . 7 . 682–683 . July 2021 . 33844998 . 8040539 . 10.1016/S2213-2600(21)00171-5 . Commentary .
  112. Web site: CAS-ViewAlert . www.cas.mhra.gov.uk . 16 April 2021 . 12 April 2021 . https://web.archive.org/web/20210412150959/https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103154 . live .
  113. Deokar K, Agarwal M, Dutt N, Chauhan N, Niwas R, Shadrach BJ, Chawla G . A review of Ciclesonide in COVID-19. Still a long way to go . Advances in Respiratory Medicine . 89 . 1 . 79–81 . 2021 . 33471354 . 10.5603/ARM.a2020.0173 . free .
  114. Web site: Dexamethasone. live. https://web.archive.org/web/20170831175940/https://www.drugs.com/monograph/dexamethasone.html. 31 August 2017. 29 July 2015. The American Society of Health-System Pharmacists.
  115. Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA, Martín-Rodríguez C, Díaz-Domínguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Añón JM, Fernández RL, González-Martín JM . Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial . The Lancet. Respiratory Medicine . 8 . 3 . 267–276 . March 2020 . 32043986 . 10.1016/s2213-2600(19)30417-5 . Early administration of dexamethasone could reduce duration of mechanical ventilation and overall mortality in patients with established moderate-to-severe ARDS. . doi . free .
  116. Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LC, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JP, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC . Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis . JAMA . 324 . 13 . 1330–1341 . October 2020 . 32876694 . 7489434 . 10.1001/jama.2020.17023 . doi . free .
  117. Web site: Corticosteroids for COVID-19. 2 September 2020. Living Guidance. WHO. 2 September 2020. 11 October 2020. https://web.archive.org/web/20201011091829/https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. live.
  118. News: 16 June 2020. Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford. 16 June 2020. 16 June 2020. https://web.archive.org/web/20200616145052/http://www.ox.ac.uk/news/2020-06-16-dexamethasone-reduces-death-hospitalised-patients-severe-respiratory-complications/. live.
  119. News: 17 June 2020. Steroid drug hailed as 'breakthrough' for seriously ill COVID-19 patients. Reuters. 18 June 2020. 2 December 2021. https://web.archive.org/web/20211202091730/https://www.reuters.com/article/uk-health-coronavirus-steroid/scientists-hail-dexamethasone-as-major-breakthrough-in-treating-covid-19-idUKKBN23N1WT. live.
  120. News: Ducharme J. A Low-Cost Steroid Shows Promise for Treating COVID-19. But Take the News With a Grain of Salt. Time. 18 June 2020. 18 June 2020. https://web.archive.org/web/20200618004432/https://time.com/5854416/dexamethasone-covid-19/. live.
  121. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. 22 June 2020 . 10.1101/2020.06.22.20137273. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B. 219965377. free . doi.
  122. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ . Dexamethasone in Hospitalized Patients with Covid-19 . The New England Journal of Medicine . 384 . 8 . 693–704 . February 2021 . 32678530 . 7383595 . 10.1056/NEJMoa2021436 .
  123. Web site: Corticosteroids (Including Dexamethasone). 12 July 2020. COVID-19 Treatment Guidelines. National Institutes of Health. 7 July 2020. https://web.archive.org/web/20200707234708/https://www.covid19treatmentguidelines.nih.gov/dexamethasone/. live.
  124. Web site: Q&A: Dexamethasone and COVID-19. 12 July 2020. World Health Organization (WHO). 11 October 2020. https://web.archive.org/web/20201011115730/https://www.who.int/news-room/q-a-detail/q-a-dexamethasone-and-covid-19/. live.
  125. Web site: COVID-19 Guideline, Part 1: Treatment and Management. 22 July 2020. Infectious Diseases Society of America. Recommendation 4. Among hospitalized patients with severe* COVID-19, the IDSA guideline panel suggests glucocorticoids rather than no glucocorticoids. (Conditional recommendation, Moderate certainty of evidence)
    Remark: Dexamethasone 6 mg IV or PO for 10 days (or until discharge if earlier) or equivalent glucocorticoid dose may be substituted if dexamethasone unavailable. Equivalent total daily doses of alternative glucocorticoids to dexamethasone 6 mg daily are methylprednisolone 32 mg and prednisone 40 mg.
    Recommendation 5. Among hospitalized patients with COVID-19 without hypoxemia requiring supplemental oxygen, the IDSA guideline panel suggests against the use of glucocorticoids. (Conditional recommendation, Low certainty of evidence). 6 October 2020. https://web.archive.org/web/20201006214733/https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management//. live.
  126. EMA starts review of dexamethasone for treating adults with COVID-19 requiring respiratory support. European Medicines Agency (EMA). 24 July 2020. 27 July 2020. 30 January 2021. https://web.archive.org/web/20210130205543/https://www.ema.europa.eu/en/news/ema-starts-review-dexamethasone-treating-adults-covid-19-requiring-respiratory-support. live. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  127. Corticosteroids for COVID-19: living guidance, 2 September 2020. World Health Organization (WHO). WHO/2019-nCoV/Corticosteroids/2020.1. ((World Health Organization)). 2020. 10665/334125. 2 September 2020. 11 October 2020. https://web.archive.org/web/20201011091829/https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. live.
  128. WHO updates clinical care guidance with corticosteroid recommendations . World Health Organization (WHO) . 23 January 2022 . 21 January 2022 . https://web.archive.org/web/20220121102721/http://www.who.int/news-room/feature-stories/detail/who-updates-clinical-care-guidance-with-corticosteroid-recommendations . live .
  129. EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. European Medicines Agency (EMA). 18 September 2020. 21 September 2020. 14 February 2021. https://web.archive.org/web/20210214060918/https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation. live. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  130. Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LC, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JP, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC . Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis . JAMA . 324 . 13 . 1330–1341 . October 2020 . 32876694 . 7489434 . 10.1001/jama.2020.17023 .
  131. Web site: 17 December 2021. A parasitic infection that can turn fatal with administration of corticosteroids. WHO. 21 February 2021. 12 December 2021. https://web.archive.org/web/20211212040459/https://www.who.int/news/item/17-12-2020-a-parasitic-infection-that-can-turn-fatal-with-administration-of-corticosteroids. live.
  132. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR . Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 . Cell . 181 . 5 . 1036–1045.e9 . May 2020 . 32416070 . 10.1016/j.cell.2020.04.026 . 7227586 .
  133. Draghici S, Nguyen TM, Sonna LA, Ziraldo C, Vanciu R, Fadel R, Morrison A, Kenney RM, Alangaden G, Ramesh M, Mor G . COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases . Bioinformatics . 37 . 17 . 2691–2698 . September 2021 . 33693506 . 10.1093/bioinformatics/btab163 . 7989618 .
  134. Draghici . Sorin . et. al . May 19, 2020 . COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases . 10.1101/2020.05.06.20076687v1.
  135. Book: Clinical Management of COVID-19, Interim Guidance . May 27, 2020 . World Health Organization.
  136. Web site: Retracted coronavirus (COVID-19) papers . Retraction Watch . 29 April 2020 .
  137. Chiscano-Camón L, Ruiz-Rodriguez JC, Ruiz-Sanmartin A, Roca O, Ferrer R . Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome . Crit Care . 24 . 1 . 522 . August 2020 . 32847620 . 7447967 . 10.1186/s13054-020-03249-y . free .
  138. Web site: Vitamin C . COVID-19 Treatment Guidelines . April 21, 2021 . January 2, 2022 . November 20, 2021 . https://web.archive.org/web/20211120131306/https://www.covid19treatmentguidelines.nih.gov/therapies/supplements/vitamin-c/ . live .
  139. Web site: COVID-19 Treatment Guidelines . 26 December 2022 . U.S. National Institutes of Health . 18 December 2023.
  140. Kow CS, Hasan SS, Ramachandram DS . The effect of vitamin C on the risk of mortality in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials . Inflammopharmacology . 31 . 6 . 3357–62 . December 2023 . 37071316. 10111321 . 10.1007/s10787-023-01200-5 .
  141. Huang WY, Hong J, Ahn SI, Han BK, Kim YJ . Association of Vitamin C Treatment with Clinical Outcomes for COVID-19 Patients: A Systematic Review and Meta-Analysis . Healthcare . 10 . 12 . December 2022 . 2456 . 36553979 . 9777834 . 10.3390/healthcare10122456 . free .
  142. Olczak-Pruc M, Swieczkowski D, Ladny JR, Pruc M, Juarez-Vela R, Rafique Z, Peacock FW, Szarpak L . Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis . Nutrients . 14 . 19 . October 2022 . 4217 . 36235869 . 9570769 . 10.3390/nu14194217 . free .
  143. Martineau AR, Forouhi NG . Vitamin D for COVID-19: a case to answer? . The Lancet. Diabetes & Endocrinology . 8 . 9 . 735–736 . September 2020 . 32758429 . 7398646 . 10.1016/S2213-8587(20)30268-0 .
  144. Web site: Vitamin D . Coronavirus Disease 2019 (COVID-19) Treatment Guidelines . 17 July 2020 . National Institutes of Health (NIH) . 22 February 2021 . 21 February 2021 . https://web.archive.org/web/20210221110534/https://www.covid19treatmentguidelines.nih.gov/supplements/vitamin-d/ . live .
  145. COVID-19 rapid guideline: vitamin D . National Institute for Health and Care Excellence (NICE) . December 2020 . PDF . 22 February 2021 . NG187 . 978-1-4731-3942-8 . 3 December 2021 . https://web.archive.org/web/20211203113126/https://www.nice.org.uk/guidance/ng187/resources/covid19-rapid-guideline-vitamin-d-pdf-66142026720709 . live .
  146. Damascena AD, Azevedo LM, Oliveira TA, Santana JD, Pereira M . Addendum to vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis . Critical Reviews in Food Science and Nutrition . 63 . 4 . 557–562 . August 2021 . 34384300 . 10.1080/10408398.2021.1951652 . 9 September 2021 . live . 236997712 . https://web.archive.org/web/20211202091734/https://pubmed.ncbi.nlm.nih.gov/34384300/ . 2 December 2021 .
  147. Kazemi A, Mohammadi V, Aghababaee SK, Golzarand M, Clark CC, Babajafari S . Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis . Advances in Nutrition . 12 . 5 . 1636–1658 . October 2021 . 33751020 . 7989595 . 10.1093/advances/nmab012 .
  148. Petrelli F, Luciani A, Perego G, Dognini G, Colombelli PL, Ghidini A . Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies . The Journal of Steroid Biochemistry and Molecular Biology . 211 . 105883 . July 2021 . 33775818 . 7997262 . 10.1016/j.jsbmb.2021.105883 .
  149. Bassatne A, Basbous M, Chakhtoura M, El Zein O, Rahme M, El-Hajj Fuleihan G . The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis . Metabolism . 119 . 154753 . June 2021 . 33774074 . 7989070 . 10.1016/j.metabol.2021.154753 . Systematic review .
  150. Evidence reviews for the use of vitamin D supplementation as prevention and treatment of COVID-19 . PDF . National Institute for Health and Care Excellence (NICE) . December 2020 . 22 February 2021 . 20 October 2021 . https://web.archive.org/web/20211020163818/https://www.nice.org.uk/guidance/ng187/evidence/evidence-reviews-for-the-use-of-vitamin-d-supplementation-as-prevention-and-treatment-of-covid19-pdf-8957587789 . live .
  151. Web site: International clinical trials assessing vitamin D in people with COVID-19. 11 June 2021. ClinicalTrials.gov. 6 October 2020. https://web.archive.org/web/20201006214952/https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=vitamin+D&cntry=&state=&city=&dist=%2F. live.
  152. Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R . Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166 . The Journal of Steroid Biochemistry and Molecular Biology . 202 . 105719 . September 2020 . 32535032 . 7289092 . 10.1016/j.jsbmb.2020.105719 .
  153. Shah K, Saxena D, Mavalankar D . Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis . QJM . 114 . 3 . 175–181 . May 2021 . 33486522 . 7928587 . 10.1093/qjmed/hcab009 .
  154. Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, Meybohm P, Becker M, Skoetz N, Stegemann M, Piechotta V . Vitamin D supplementation for the treatment of COVID-19: a living systematic review . The Cochrane Database of Systematic Reviews . 2021 . 5 . CD015043 . May 2021 . 34029377 . 8406457 . 10.1002/14651858.CD015043 . 235202971 .
  155. Cesareo R, Falchetti A, Attanasio R, Tabacco G, Naciu AM, Palermo A . Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol? . Nutrients . 11 . 5 . 1016 . May 2019 . 31064117 . 6566727 . 10.3390/nu11051016 . Review . free .
  156. Web site: Zinc . Coronavirus Disease 2019 (COVID-19) Treatment Guidelines . 21 April 2021 . National Institutes of Health (NIH) . 28 November 2021 . 10 November 2021 . https://web.archive.org/web/20211110232118/https://www.covid19treatmentguidelines.nih.gov/therapies/supplements/zinc/ . live .
  157. Web site: Coronavirus: Scientists could repurpose drugs to treat infection. 20 March 2020. Medical News Today. 28 February 2020. 17 March 2020. https://web.archive.org/web/20200317122937/https://www.medicalnewstoday.com/articles/coronavirus-existing-drugs-could-be-repurposed-to-treat-infection. live.
  158. Existing Drugs May Offer a First-Line Treatment for Coronavirus Outbreak. 20 March 2020. Global Health News Wire. 3 May 2020. https://web.archive.org/web/20200503113955/https://globalhealthnewswire.com/viruses-vaccines/2020/02/27/existing-drugs-may-offer-a-first-line-treatment-for-coronavirus-outbreak. live.
  159. Firth A, Prathapan P . Broad-spectrum therapeutics: A new antimicrobial class . Current Research in Pharmacology and Drug Discovery . 2 . 100011 . 1 January 2021 . 34870144 . 8035643 . 10.1016/j.crphar.2020.100011 . doi . free .
  160. Firth A, Prathapan P . Azithromycin: The First Broad-spectrum Therapeutic . European Journal of Medicinal Chemistry . 207 . 112739 . December 2020 . 32871342 . 7434625 . 10.1016/j.ejmech.2020.112739 .
  161. Web site: Biodefense Strategic Plan . NIH: National Institute of Allergy and Infectious Diseases . 7 August 2015 . 2 February 2021 . 31 January 2021 . https://web.archive.org/web/20210131090628/https://www.niaid.nih.gov/research/biodefense-strategic-plan . live.
  162. Web site: 18 September 2015. NIH funds development of new broad-spectrum therapeutics. 2 February 2021. National Institutes of Health (NIH). 28 January 2021. https://web.archive.org/web/20210128161347/https://www.nih.gov/news-events/news-releases/nih-funds-development-new-broad-spectrum-therapeutics. live.
  163. Baron SA, Devaux C, Colson P, Raoult D, Rolain JM . Teicoplanin: an alternative drug for the treatment of COVID-19? . International Journal of Antimicrobial Agents . 55 . 4 . 105944 . April 2020 . 32179150 . 7102624 . 10.1016/j.ijantimicag.2020.105944 .
  164. Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjørås M, Telling K, Lutsar I, Dumpis U, Irie Y, Tenson T, Kantele A, Kainov DE . Discovery and development of safe-in-man broad-spectrum antiviral agents . International Journal of Infectious Diseases . 93 . 268–276 . April 2020 . 32081774 . 7128205 . 10.1016/j.ijid.2020.02.018 .
  165. Web site: 22 March 2020. Amid Ongoing COVID-19 Pandemic, Governor Cuomo Accepts Recommendation of Army Corps of Engineers for Four Temporary Hospital Sites in New York. governor.ny.gov. 24 March 2020. 6 October 2020. https://web.archive.org/web/20201006215100/https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-accepts-recommendation-army-corps-engineers-four/. live.
  166. Revive Therapeutics Ltd. 31 July 2020. Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19. 5 August 2020. GlobeNewswire. 6 October 2020. https://web.archive.org/web/20201006214457/http://www.globenewswire.com/news-release/2020/07/31/2071193/0/en/UPDATE-Revive-Therapeutics-Announces-U-S-FDA-Approval-of-Confirmatory-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html. live.
  167. Web site: Marcelli S . 2020-10-13 . Pasteur Lille obtient 5 M€ de LVMH pour repositionner un ancien médicament, l'Octofene, sur le traitement du Covid . Pasteur Lille obtains €5 million from LVMH to reposition an old drug, Octofene, for the treatment of Covid . https://web.archive.org/web/20201017080026/https://www.aefinfo.fr/depeche/637456-pasteur-lille-obtient-5-m-de-lvmh-pour-repositionner-un-ancien-medicament-l-octofene-sur-le-traitement-du-covid . 2020-10-17 . 2020-10-13 . AEF info . fr.
  168. Web site: Mounier JL . 2020-10-01 . French institute aims to start human trials of 'promising' Covid-19 drug this winter . https://web.archive.org/web/20201001123214/https://www.france24.com/en/20201001-french-institute-aims-to-start-human-trials-of-promising-covid-19-drug-this-winter . 2020-10-01 . 2024-06-02 . France 24 . en.
  169. Web site: Thomas L . 2022-05-23 . Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study . https://web.archive.org/web/20220523092640/https://www.news-medical.net/news/20220523/Repurposed-drug-clofoctol-blocks-SARS-CoV-2-replication-in-mouse-study.aspx . 2022-05-23 . 2024-06-02 . News-Medical . en.
  170. Belouzard S, Machelart A, Sencio V, Vausselin T, Hoffmann E, Deboosere N, Rouillé Y, Desmarets L, Séron K, Danneels A, Robil C, Belloy L, Moreau C, Piveteau C, Biela A, Vandeputte A, Heumel S, Deruyter L, Dumont J, Leroux F, Engelmann I, Alidjinou EK, Hober D, Brodin P, Beghyn T, Trottein F, Deprez B, Dubuisson J . Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice . PLOS Pathogens . 18 . 5 . e1010498 . May 2022 . 35587469 . 9119441 . 10.1371/journal.ppat.1010498 . free . Menachery VD .
  171. Web site: Début d'une étude clinique pour tester un médicament contre les effets de la COVID-19 Coronavirus. Radio-Canada.ca. 12 April 2020. 14 April 2020. https://web.archive.org/web/20200414110417/https://ici.radio-canada.ca/nouvelle/1681600/traitement-coronavirus-covid19-tardif-montreal-canada-quebec-colcorona. live.
  172. Web site: COLCORONA Clinical Trial Stop COVID-19. Colcorona. 1 May 2020. 13 August 2020. https://web.archive.org/web/20200813020503/https://en.colcorona.net/. dead.
  173. The SARS-CoV-2 Transcriptional Metabolic Signature in Lung Epithelium . Ehrlich A, Uhl S, Ioannidis K, Hofree M, tenOever BR, Nahmias Y . 14 July 2020 . 3650499.
  174. Web site: Antiviral Drug Reduces COVID-19 Inflammation In 48 Hours, Israeli Study Finds. 24 August 2021. 28 August 2021. 28 August 2021. https://web.archive.org/web/20210828160634/https://nocamels.com/2021/08/antiviral-drug-reduces-covid-19-inflammation-in-48-hours-israeli-study-finds/. live.
  175. Web site: Cholesterol Drug May Downgrade COVID-19 Threat - New Study. 29 July 2020. 28 August 2021. 28 August 2021. https://web.archive.org/web/20210828160631/https://nocamels.com/2020/07/cholesterol-drug-covid-19-common-cold-study/. live.
  176. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma. 10 September 2020. ClinicalTrials.gov. 5 March 2020. 29 July 2020. https://web.archive.org/web/20200729001132/https://clinicaltrials.gov/ct2/show/NCT04234048. live.
  177. 26 April 2020. New York clinical trial quietly tests heartburn remedy against coronavirus. Science. 29 April 2020. 29 April 2020. https://web.archive.org/web/20200429193819/https://www.sciencemag.org/news/2020/04/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus. live.
  178. Web site: LIBERATE Trial in COVID-19 (LIBERATE). 10 September 2020. ClinicalTrials.gov. 6 October 2020. https://web.archive.org/web/20201006215117/https://clinicaltrials.gov/ct2/show/NCT04334629/. live.
  179. News: 3 June 2020. Coronavirus: Ibuprofen tested as a treatment. BBC News Online. 4 June 2020. 6 October 2020. https://web.archive.org/web/20201006215137/https://www.bbc.com/news/health-52894638/. live.
  180. Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer AP, Daubenberger C, Brentani A . Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil . BMJ Evidence-Based Medicine . December 2020 . 26 . 4 . 192–193 . 33310766 . 7735072 . 10.1136/bmjebm-2020-111549 . Covid-19 patients with recent influenza vaccination experience better health outcomes than non-vaccinated patients in Brazil. .
  181. A Pilot Study of Sildenafil in COVID-19. 10 September 2020. ClinicalTrials.gov. 14 March 2020. Ning Q. 4 September 2020. https://web.archive.org/web/20200904165135/https://clinicaltrials.gov/ct2/show/NCT04304313. live.
  182. Web site: No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK. 7 June 2020. 5 June 2020. 8 October 2020. https://web.archive.org/web/20201008142832/https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19. live.
  183. Web site: Horby P, Landray M . RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 . RECOVERY Trial . 14 December 2020 . 8 March 2022 . 8 March 2022 . https://web.archive.org/web/20220308061410/https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19 . live .
  184. Kupferschmidt K . Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds . . 3 March 2022 . 10.1126/science.adb1803 . free . doi .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "COVID-19 drug repurposing research".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.